Immunosuppressive therapy for ocular diseases

Current Opinion in Ophthalmology

Volumn 19, Issue 6, 2008, Pages 535-540

  Jap, Aliza ^a,b   Chee, Soon Phaik ^b,c,d,e  

^a CHANGI GENERAL HOSPITAL   (Singapore)

^b SINGAPORE NATIONAL EYE CENTRE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^e NONE   (Singapore)

Author keywords

Biologics; Mycophenolate mofetil; Ocular inflammation

Indexed keywords

ADALIMUMAB; ALPHA2A INTERFERON; BIOLOGICAL RESPONSE MODIFIER; CYCLODEXTRIN; CYCLOSPORIN; CYTOKINE ANTIBODY; CYTOKINE RECEPTOR ANTAGONIST; DACLIZUMAB; DAPSONE; DEXAMETHASONE; ETANERCEPT; FLUOCINOLONE ACETONIDE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NANOSPHERE; RAPAMYCIN; STEROID; SULFANILAMIDE DERIVATIVE; TACROLIMUS; TRIAMCINOLONE ACETONIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ALOPECIA; BEHCET DISEASE; BLOOD PRESSURE; BLURRED VISION; BURNING SENSATION; CATARACT; CELLULITIS; CHORIORETINOPATHY; CONJUNCTIVAL HYPEREMIA; CYTOMEGALOVIRUS INFECTION; DEPRESSION; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG IMPLANT; DRY EYE; ECZEMA; ENDOPHTHALMITIS; EPILEPSY; EYE DISEASE; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEADACHE; HUMAN; HYPEREMIA; IMMUNOSUPPRESSIVE TREATMENT; INSOMNIA; INTRAOCULAR HYPERTENSION; KERATOPATHY; LEUKOPENIA; LUPUS LIKE SYNDROME; LYMPHOCYTOPENIA; NEOVASCULAR GLAUCOMA; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; PANCREATITIS; PARESTHESIA; PRIORITY JOURNAL; RASH; RETINOPATHY; REVIEW; SIDE EFFECT; SUICIDE ATTEMPT; TUBERCULOSIS; UVEITIS; VIRUS ENCEPHALITIS;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INTERFERON ALFA-2A; MYCOPHENOLIC ACID; RECEPTORS, TUMOR NECROSIS FACTOR; UVEITIS;

EID: 56249094542     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e3283126d20     Document Type: Review

References (51)

1. Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporine versus colchicine and long-term open study of cyclosporine in Behcet's disease. Lancet 1989; 1:1093-1096.
2. Yazici J, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med 1990; 322:281-285.
3. Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol 2007; 18:481-486.
4. Lim L, Suhler EB, Smith JR. Biologic therapies for inflammatory eye disease. Clin Experiment Ophthalmol 2006; 34:365-374.
5. Sobrin L, Kim EC, Christen W, et al. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 2007; 125:895-900. This retrospective study of 27 patients with refractory ocular inflammation treated with infliximab showed a high efficacy with minimal adverse reactions.
6. Sfikakis PP, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behcet's disease: review and basis for recommendations. Rheumatology 2007; 46:736-741. This is an expert panel review on the role on anti-TNF agents in Behcet's disease.
7. Niccoli L, Nannini C, Benucci M, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study. Rheumatology 2007; 46:1161-1164.
8. Accorinti M, Pirraglia MP, Paroli MP, et al. Infliximab treatment for ocular and extraocular manifestations of Behcet's disease. Jpn J Ophthalmol 2007; 51:191-196.
9. Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet's disease. Ann Intern Med 2004; 140:404-406.
10. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 2004; 31:1362-1368.
11. Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is refractory to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease: an open-label trial. Arthritis Rheum 2005; 52:2478-2484.
12. Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sight-threatening uveitis in Behcet's disease. Eye 2007; 21:824-825.
13. Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006; 113:2317-2323.
14. Nussenblatt RB, Peterson JS, Foster CS, et al. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter non-comparative interventional case series. Ophthalmology 2005; 112:764-770.
15. Sobrin L, Huang JJ, Christen W, et al. Daclizumab for treatment of birdshot chorioretinopathy. Arch Ophthalmol 2008; 126:186-191.
16. Buggage RR, Levy-Clarke G, Sen HN, et al. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behcet's disease. Ocul Immunol Inflamm 2007; 15:63-70.
17. Li B, Yang P, Zhou H, et al. T-bet expression is up-regulated in active Behcet's disease. Br J Ophthalmol 2003; 87:1264-1267.
18. Plskova J, Greiner K, Forrester JV. Interferon-α as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol 2007; 144:55-61.
19. Bodaghi B, Gendron G, Weschler B, et al. Efficacy of Interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 2007; 91:335-433. This large retrospective series found IFN-α to be efficacious in the management of severe uveitis.
20. Gallagher M, Quinones K, Cervantes-Castaneda RA, et al. Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol 2007; 91: 1341-1344. This small case series shows that adalimumab and daclizumab are potentially useful and well tolerated in the treatment of JIA-U and other severe childhood uveitis.
21. Ardoin SP, Kredich D, Rabinovich E, et al. Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am J Ophthalmol 2007; 144:844-849. This study found infliximab to be a well tolerated and effective adjunct in a variety of paediatric uveitis for at least 24 months.
22. Vazquez-Cobian LB, Flynn T, Lehman TJA. Adalimumab therapy for childhood uveitis. J Pediatr 2006; 149:572-575.
23. Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007; 91:319-324. Adalimumab was used to treat 18 children with mainly JIA-U and was found to be effective in controlling uveitis in 88% of them.
24. Tynjälä P, Lindhal P, Honkanen V, et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007; 66:548-550. Etanercept was found to be less effective in 45 JIA-U children than infliximab.
25. Saurenmann RK, Levin AV, Rose JB, et al. Tumour necrosis factor α inhibitors in the treatment of childhood uveitis. Rheumatology 2006; 45:982-989.
26. Fonollosa A, Segura A, Giralt J, Garcia-Arumi J. Tuberculous uveitis after treatment with etanercept. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1397-1399.
27. Doycheva D, Deuter C, Stuebiger N, et al. Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol 2007; 91:180-184. MMF is another useful adjunct for the management of idiopathic paediatric intermediate uveitis, with minimal side effects.
28. Siepmann K, Huber M, Stübinger N, et al. Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis: a retrospective analysis of 106 patients. Graefes Arch Clin Exp Ophthalmol 2006; 244:788-794.
29. Hoffman PE, McKelvie P, Hall AJ, et al. Intraocular lymphoma: a series of 14 patients with clinicopathological features and treatment outcomes. Eye 2003; 17:513-521.
30. Isobe K, Ejima Y, Tokumara S, et al. Treatment of primary intraocular lymphoma with radiation therapy: a multiinstitutional survey in Japan. Leuk Lymphoma 2006; 47:1800-1805.
31. Batchelor TT, Kolak G, Ciordia R, et al. High-dose methotrexate for intraocular lymphoma. Clin Cancer Res 2003; 9:711-715.
32. Frenkel S, Hendler K, Siegal T, et al. Intravitreal methotrexate for treating vitreoretnal lymphoma: 10 years of experience. Br J Ophthalmol 2008; 92:383-388. Intravitreal methotrexate achieved remission of intraocular lymphoma in all 44 eyes of 26 patients who were treated.
33. Price MO, Price FW Jr. Efficacy of topical cyclosporine 0.05% for prevention of cornea transplant rejection episodes. Ophthalmology 2006; 113:1785-1790.
34. Wilson SE, Perry HD. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Ophthalmology 2007; 114:76-79.
35. Pflugfelder SC, De Paiva CS, Villarreal AL, Stern ME. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-62 production. Cornea 2008; 27:64-69.
36. Ozcan AA, Ersoz TR, Dulger E. Management of severe allergic conjunctivitis with topical cyclosporine A 0.05% eyedrops. Cornea 2007; 26:1035-1038.
37. Joseph A, Raj D, Shanmuganathan V, et al. Tacrolimus immunosuppression in high-risk corneal grafts. Br J Ophthalmol 2007; 91:51-55. Graft clarity was maintained in 43 high-risk corneal graft patients treated with systemic tacrolimus.
38. Stumpf T, Luqmani N, Sumich P, et al. Systemic tacrolimus in the treatment of severe atopic keratoconjunctivitis. Cornea 2006; 25:1147-1149.
39. Kymionis GD, Goldman D, Ide T, Yoo SH. Tacrolimus ointment 0.03% in the eye for treatment of giant papillary conjunctivitis. Cornea 2008; 27:228-229.
40. Virtanen HM, Reitamo S, Kari M, Kari O. Effect of 0.03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis: a retrospective study. Acta Ophthalmol Scand 2006; 84:693-695.
41. Saw VP, Dart JK, Rauz S, et al. Immunosuppressive therapy for ocular mucous membrane pemphigoid: strategies and outcomes. Ophthalmology 2008; 115:253-261.
42. Kempen JH, Daniel E, Gangaputra S, et al. Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol 2008; 15:47-55.
43. Mezalek ZT, Harmouche H, El Attar N, et al. Kaposi's sarcoma in association with Behcet's disease: case report and literature review. Semin Arthritis Rheum 2007; 36:328-331.
44. Delyfer MN, Rougier MB, Hubschman JP, et al. Cytomegalovirus retinitis following intravitreal injection of triamcinolone: report of two cases. Acta Ophthalmol Scand 2007; 85:681-683.
45. Saidel MA, Berreen J, Margolis TP. Cytomegalovirus retinitis after intravitreous triamcinolone in an immunocompetent patient. Am J Ophthalmol 2005; 140:1141-1143.
46. Ufret-Vincenty RL, Singh RP, Lowder CY, Kaiser PK. Cytomegalovirus retinilis after fluocinolone acetonide (Retisert) implant. Am J Ophthalmol 2007; 143:334-335.
47. Lee SS, Kim H, Wang NS, et al. A pharmacokinetic and safety evaluation of an episcleral cyclosporine implant for potential use in high-risk keratoplasty rejection. Invest Ophthalmol Vis Sci 2007; 48:2023-2029.
48. Fei WL, Chen JQ, Yuan J, et al. Preliminary study of the effect of FK506 (tacrolimus) nanospheric-suspension eye drops on rejection of penetrating keratoplasy. J Ocul Pharmacol Ther 2008; 24:235-244.
49. Shi W, Gao H, Xie L, Wang S. Sustained intraocular rapamycin delivery effectively prevents high-risk comeal allograft rejection and neovascularization in rabbits. Invest Ophthalmol Vis Sci 2006; 47:3339-3344.
50. Eljarrat-Binstock E, Domb AJ, Orucov F, et al. Methotrexate delivery to the eye using transscleral hydrogel iontophoresis. Curr Eye Res 2007; 32:639-646.
51. Loftsson T, Hreindóttir D, Stefánsson E. Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops. J Pharm Pharmacol 2007; 59:629-635.